Here's your news in brief: Gene therapies are continuing to make their way onto the scene, with Kite Pharma Inc.'s chimeric antigen receptor T-cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) becoming the second gene therapy to win a US FDA approval.
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
The latest drug development news and highlights from our US FDA Performance Tracker.
